POSTDOCTORAL / EXPERIENCED RESEARCHER MSCA FELLOWSHIP IN EPIGENETIC THERAPIES
Deadline for application
Applicants must have a compelling track record appropriate to their career stage of peer-reviewed publication(s) in internationally recognized outlets, conference invitations or other indicators of success and must meet the Scheme’s eligibility requirements, outlined below:
- Be in the possession of a doctoral degree or have at least four years of full-time equivalent research experience at the time of the call deadline.
- Comply with the mobility rule: you cannot apply for a fellowship in our institution if you do not meet the call mobility rule -> might change depending on the type of MSCA IF.
What we offer?
We offer the opportunity to contribute to cutting‐edge research projects in a competitive and dynamic international environment, in one of the leading Epigenetics labs in the world.
The MSCA-IF grant provides living allowance covering one to two years' salary, a mobility allowance, as well as research, training and networking costs, which translates in a very competitive salary conditions to the average cost of living in Barcelona, which is a dynamic, vibrant and multi-cultural European capital city.
For more information about the financial aspects, you can check the Guide for applicants.
Please note, that a labour contract with IJC includes automatically your registration in the Spanish Social Security System, covering you in term of medical assistance. Consequently, you will pay social security contributions and Personal taxes, deducted directly from the gross salary. For more information, please visit Tax Agency.
We welcome applications from outstanding researchers eager to study Epigenetic Therapies at Research Group of Dr. María Berdasco for the Marie Sklodowska-Curie Actions Individual Fellowships Call.
The Epigenetic Therapies Group is focused on elucidating which epigenetic alterations are druggable targets in a tumor, and the means for their therapeutic exploitation in the framework of Personalised Medicine. To this end, we will aim at answering three key questions:
1. Identification of the epigenetic alterations acting as drivers of the tumor progression (“druggable epigenetic alterations”). We apply the new possibilities offered by CRISPR-dCas9 directed genome targeting to set up epigenome editing systems that target DNA methylation and demethylation to differentially methylated regions identified in cancer cells. By combining these methods and in vitro proliferation assays, we identify those methylation changes that directly stimulate growth of healthy cells or inhibit growth of cancerous ones.
2. Validation of epidrugs that can efficiently revert aberrant epigenomes in cancer. To reach this goal, we determine the therapeutic effect in vitro of drugs in cell lines with and without genetic defects. We perform basic functional assays to test their potential inhibitory effect on tumorogenesis (e.g., MTT, colony formation, wound healing, transwell migration assays, flow cytometry or apoptosis). In parallel, we study the genome-wide epigenetic pattern before and after the treatment with epigenetic drugs to identify main targeted pathways (eg. CpG methylation arrays for DNMT inhibitors or Chip-seq for histone modifiers drugs).
3. Stratification of patients based on their epigenetic profile to predict response. We aim to identify epigenetic biomarkers of clinical response to chemotherapy and advanced therapies in haematological cancer.
Please also visit our group webpage:
More information can be obtained by consulting the MSCA-IF call page in the Funding and Tenders Portal and the Horizon 2020 Work Programme 2018-2020 / Section 3. Marie Skłodowska-Curie actions.
NOTE: Exceptional situations or career breaks can be taken into consideration, if a justification is provided.
Who we are?
The Josep Carreras Leukaemia Research Institute (IJC) is a non-profit research institute based in Barcelona and dedicated to advancing our understanding about leukaemia and related disorders, in partnership with the University of Barcelona and University Autònoma of Barcelona. The IJC has laboratories in three clinical campuses: i) Clinic Hospital, ii) Sant Pau Hospital and iii) Germans Trias i Pujol Hospital. IJC serves as a collaborative hub for basic investigators and physicians to work together on fundamental biological and clinical aspects of leukaemia. The IJC offers an excellent work environment built around a multi-disciplinary fusion of ideas and state-of-the-art facilities.
Our mission is to carry out research into the basic, epidemiological, preventive, clinical and translational aspects of leukemia and other hematologic malignancies.
The vision of the Josep Carreras Leukaemia Research Institute is that research will identify new therapeutic targets and enable us to develop more precise and less aggressive treatments. We aspire to understand the origin and development of leukemias and other malignant haematological pathologies in order to be able to prevent them. We will work for a future in which all leukemias will be curable.
The Josep Carreras Institute is member of the Research Centers of Excellence of Catalonia (CERCA, Catalan Government), also accredited by the Spanish Ministry of Health as Health Research Centre of Excellence (ISCIII) and by the Spanish Association Against Cancer (Asociación Española contra el Cáncer, AEEC). The institute also holds the HR Excellence in Research recognition awarded by the European Commission.
The European Commission awarded the IJC the HR Excellence seal in July 2019. The IJC continues to work to maintain its policies in line with the Charter and Code principles.
The HRS4R has the main objective of ensuring that research centers of excellence implement and respect the requirements of the European Charter for Researchers and the Code of Conduct for hiring researchers (from here on referred to as the Charter and Code) within their human resources policies.
This EC initiative aims to promote training, professional development, and mobility for all European scientists. The IJC supports these values and principles, which will not only serve to strengthen its internal policies but will actively stimulate excellent research and firmly situate the organization as an institution with a stimulating working environment that favours the development of its scientists.
IJC is an equal opportunity employer. We evaluate qualified applicants without regard to race, colour, religion, sex, national origin, disability, and other legally protected characteristics.
Place of presentation of the candidacies
How to apply?
If you are ready to take the next step in your research career send your expression of interest and if the Scientific Supervisor accepts your candidature, you will jointly submit an Individual Fellowship proposal to the open European Commission call. Therefore, you must be available to work in the MSCA-IF proposal application between June and the first week of September 2020, considering that the call deadline is 09/09/2020.
Candidates must send an updated two-page CV with the contact details of 2 referees, a motivation letter and a one-page research project outline to firstname.lastname@example.org indicating in the subject of the message: MSCA_MBER2020 candidate.
Deadline for Applications:
Deadline expression of interest: may 25th 2020
The candidates will be informed of the pre-selection results no more than two weeks after the expression of interest deadline.
Deadline MSCA-IF call: September 9th 2020
Decisions will be announced in February 2021, after which the selected candidates can start their fellowship. An attractive feature of MSCA-IF is the flexibility of the European Commission (EC) in fixing the start date of funded projects. If necessary, this date could be delayed up to 18 months after the signing of the Grant Agreement. In the current call (2019), it would mean that projects could delay until mid-2021. The fellows be able to optimize the end date of other research contracts through this possibility.